Dimosthenis Andreou1, Magdalena M Gilg2, Georg Gosheger3, Mathias Werner4, Jendrik Hardes3, Daniel Pink5, Andreas Leithner2, Per-Ulf Tunn6, Arne Streitbürger3. 1. Department of General Orthopedics and Tumor Orthopedics, Münster University Hospital, Münster, Germany. dimosthenis.andreou@ukmuenster.de. 2. Department of Orthopedic Surgery, Medical University of Graz, Graz, Austria. 3. Department of General Orthopedics and Tumor Orthopedics, Münster University Hospital, Münster, Germany. 4. Department of Pathology, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Emil von Behring, Berlin, Germany. 5. Department of Hematology, Oncology and Palliative Care, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, Bad Saarow, Germany. 6. Department of Orthopedic Oncology, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
Abstract
BACKGROUND: Little is known about the metastatic potential of low-grade chondrosarcoma. This study was designed to evaluate the rate of metastasis to identify possible risk factors. METHODS: The files of 225 patients with newly diagnosed, grade I chondrosarcoma of bone treated between 1975 and 2012 were retrospectively analyzed. Median follow-up was 80 months for survivors (range 24-445 months). Nonparametric analyses were performed with the Mann-Whitney U test. Survival curves were calculated with the Kaplan-Meier method and compared with the log-rank test. RESULTS: Fourteen patients developed metastases after a median of 49 months. Metastasis-free survival probability (MFS) was 95 % at 5 years and 92 % at 10 years. Post-metastasis survival probability amounted to 27 % after 5 years. Tumor size at diagnosis (P = 0.698) and surgical margin width (P = 0.514) had no influence on MFS. Patients who developed local recurrences had a significantly lower 10-year MFS than patients without recurrences (69 % vs. 99 %, P < 0.001). Patients with grade I recurrences had a significantly poorer MFS than patients without recurrences (P = 0.013) but a significantly higher MFS than patients with grade II recurrences (P = 0.006). Patients with thoracic wall tumors had a significantly lower 10-year MFS of 66 % compared with patients with tumors of the upper (100 %, P < 0.001) and lower extremity (93 %, P = 0.033). CONCLUSIONS: The biological behavior of low-grade chondrosarcoma appears to be more consistent with the WHO definition of rarely metastasizing bone tumors, rather than the one of locally aggressive neoplasms. Thoracic wall tumors and the development of local recurrences were associated with a higher metastasis rate in this study.
BACKGROUND: Little is known about the metastatic potential of low-grade chondrosarcoma. This study was designed to evaluate the rate of metastasis to identify possible risk factors. METHODS: The files of 225 patients with newly diagnosed, grade I chondrosarcoma of bone treated between 1975 and 2012 were retrospectively analyzed. Median follow-up was 80 months for survivors (range 24-445 months). Nonparametric analyses were performed with the Mann-Whitney U test. Survival curves were calculated with the Kaplan-Meier method and compared with the log-rank test. RESULTS: Fourteen patients developed metastases after a median of 49 months. Metastasis-free survival probability (MFS) was 95 % at 5 years and 92 % at 10 years. Post-metastasis survival probability amounted to 27 % after 5 years. Tumor size at diagnosis (P = 0.698) and surgical margin width (P = 0.514) had no influence on MFS. Patients who developed local recurrences had a significantly lower 10-year MFS than patients without recurrences (69 % vs. 99 %, P < 0.001). Patients with grade I recurrences had a significantly poorer MFS than patients without recurrences (P = 0.013) but a significantly higher MFS than patients with grade II recurrences (P = 0.006). Patients with thoracic wall tumors had a significantly lower 10-year MFS of 66 % compared with patients with tumors of the upper (100 %, P < 0.001) and lower extremity (93 %, P = 0.033). CONCLUSIONS: The biological behavior of low-grade chondrosarcoma appears to be more consistent with the WHO definition of rarely metastasizing bone tumors, rather than the one of locally aggressive neoplasms. Thoracic wall tumors and the development of local recurrences were associated with a higher metastasis rate in this study.
Authors: Julian Fromm; Alexander Klein; Andrea Baur-Melnyk; Thomas Knösel; Lars Lindner; Christof Birkenmaier; Falk Roeder; Volkmar Jansson; Hans Roland Dürr Journal: World J Surg Oncol Date: 2019-09-03 Impact factor: 2.754
Authors: Julian Fromm; Alexander Klein; Andrea Baur-Melnyk; Thomas Knösel; Lars Lindner; Christof Birkenmaier; Falk Roeder; Volkmar Jansson; Hans Roland Dürr Journal: BMC Cancer Date: 2018-08-24 Impact factor: 4.430
Authors: Claudia Deckers; Bart H W Schreuder; Gerjon Hannink; Jacky W J de Rooy; Ingrid C M van der Geest Journal: J Surg Oncol Date: 2016-10-03 Impact factor: 3.454
Authors: Zhong Li; Ge Chen; Yi Xiang; Aikeremujiang Muheremu; Xianzhe Wu; Peng He; Huaquan Fan; Juncai Liu; Chang Chen; Liu Yang; Fuyou Wang Journal: J Int Med Res Date: 2020-10 Impact factor: 1.671